| | | | | 黏液样/圆细胞型脂肪肉瘤中FUS-CHOP融合基因和MDM_2蛋白的表达及意义 | | | 王岩;魏万里;张丽娟;陈芸;代自超 | | | 目的探讨FUS-CHOP融合基因与MDM2蛋白在黏液样/圆细胞型脂肪肉瘤(MRCLs)组织中的表达及意义。方法收集MRCLs标本25例。以非MRCLs的脂肪肉瘤及其它软组织肿瘤共18例作对照组。用嵌套式RT-PCR的方法检测FUS-CHOP融合基因mRNA并经和DNA测序证实,以β-actin基因作为内对照。用免疫组化S-P法检测25例MRCLs中MDM2蛋白表达情况。结果MRCLs组和对照组β-actin阳性率分别为72.0%(18/25)和66.7%(12/18)。25例MRCLs中15例检出型FUS-CHOP融合基因表达,阳性率为(60.0%),去除β-actin阴性病例的阳性率为83.3%(15/18)。对照组18例标本未检出FUS-CHOP融合基因。MRCLs中MDM2蛋白阳性表达率为56.0%(14/25),在圆细胞为主的病例组阳性表达率最高,差异有显著性。FUS-CHOP融合基因与MDM2蛋白表达无相关性。结论(1)MRCLs中FUS-CHOP融合基因与MDM2蛋白的表达无相关性。(2)FUS-CHOP融合基因在MRCLs中呈特异性表达,可作为该肿瘤的特异性标志物用于诊断。(3)MDM2蛋白过表达与MRCLs的进展相关。
【作者单位】：云南省肿瘤医院病理科 云南昆明650118
【关键词】：脂肪肉瘤,黏液样/病理学;RNA结合蛋白质FUS;基因表达;癌基因蛋白质类,融合/遗传;诊断,鉴别;脂肪肉瘤,黏液样/诊断
【分类号】：R738
【DOI】：CNKI:SUN:SYZZ.0.2008-02-024
【正文快照】：
黏液样/圆细胞型脂肪肉瘤(myxiod/round cell liposarcoma,MRCLs)是成人脂肪肉瘤中最常见的类型之一,常发生在下肢深部软组织和腹膜后。细胞和分子遗传学研究表明,在95%以上的MRCLs有特异性的染色体易位t(12;16)(q13;p11),从而形成FUS-CHOP融合基因[1]。同时发现在人类染色体12 | | |  推荐 CAJ下载  PDF下载 | | | CAJViewer7.0阅读器支持所有CNKI文件格式，AdobeReader仅支持PDF格式 | | | | Expression of FUS-CHOP fusion gene and MDM_2 protein in myxoid/round cell liposarcoma and its significance | | | WANG Yan;WEI Wan-li;ZHANG Li-juan;et al (Department of Pathology;Cancer Hospital;Yunnan;Kunming;650118;China) | | | Objective To investigate the expression of FUS-CHOP mRNA and MDM2 protein in myxoid/round cell liposarcoma (MRCLs) and its significance. Methods Twenty five formalin-fixed, paraffin-embedded MRCL samples and 18 control cases were retrieved from the archival files. Nested reverse transcription-polymerase chain reaction(RT-PCR)technique was employed to detect the FUS-CHOP mRNA expression, followed by DNA sequencing to confirm the PCR product. β-actin mRNA was used for internal quality control. Immunohistochemical staining was used to detect the expression of MDM2 protein. Results β-actin mRNA was detected in 72.0% of MRCLs (18/25,) and 66.7% negative controls (12/18). TypeⅡ FUS-CHOP fusion transcript was successfully detected in 15 out of 25(60.0%) MRCLs. All 18 negative control cases were negative for the FUS-CHOP fusion gene transcripts. The positive rate of MDM2 protein was 56.0% (14/25), that was much higher in round cell liposarcoma than in myxoid and mixed liposarcoma. There was a negative correlation between FUS-CHOP and MDM2.Conclusion FUS-CHOP may be used as a specific molecular and genetic hallmark in diagnosis of MRCLs. The overexpression of MDM2 protein is associated with the progression in MRCLs.
【Keyword】：liposarcoma,myxoid/pathology;RNA-binding protein FUS;gene expression;oncogene proteins,fusion/genetic;dignosis,differential;liposarcoma,myxoid/diagnosis |
| | | | | | 1 | Hisaoka M, Tsuji S, Morimitsu Y et al; Detection of TLS/FUSCHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues [M];Diagnostic Molecular Pathology; 1998年 | | 2 | P ilotti S,D ella Torre G,M ezzelan i A,et al; The expression ofMDM2/CDK4 gene product in the d ifferential d iagnosis ofwell d iffer-entiated liposarcoma and large deep-seated lipoma[J] [M];B r J Cancer; 2000年 | | 3 | Dei Tos AP,Piccinin S,Doglioni C,et al; Molecular abnormalities of the G1-S checkpoint in myxiod and round liposarcoma[J] [M];Am J Pthol; 1997年 | | 4 | Antonescu CR,Sylvia J,Decuseara R; Prognostic impact of p53status,TLS-CHOP fusion transcript structure,and histological grade in myxiodliposarcoma:A molecular and clinicopathologic study of82cases[J] [M];Clini Cancer Res; 2001年 | | 5 | Kuroda M,Ishida T,Takanashi M,et al; Oncogenic transformation and inhibitor of adipocytic conversion of preadipocytes by TLS/FUS-CHOP Type chimeric protein[J] [M];AM J Pathol; 1997年 | | 6 | Pilotti S,Della TG,Lavarino C,et al; Distinct MDM2/P53expression patterns in liposarcoma subgroups:implications for different pathogenetic mechanism[J] [M];J Pathol; 1997年 | | 7 | Knight JC,Renwick PJ,Palcin P,et al; Translocation t(12;16)(q13;p11)in myxiod liposarcoma and round cell liposarcoma:molecular and cytogenetic analysis[J] [M];Cancer Res; 1995年 |
|
| | | | | | 1 | Lozano G, Monies de Oca Luna R; MDM2 function [M];Biochim BiophysActa; 1998年 | | 2 | Honda R, Tanaka H, Yasuda H; Oncoprotein MDM2 is a ubiquitin ligaseE3 for tumor suppressor p53 [M];FEBSLett; 1997年 | | 3 | Kamljo T, Weber JD, Zambetti G,et al; Functional a nd physicalinteractions of the ARF tumorsuppressor with p53 and MDM2 [M];Proc Natl Acad Sci USA; 1998年 | | 4 | Piette J, Neel H, Marechal V; MDM2: keeping p53 under control [M];Oncogene; 1997年 | | 5 | Grossman SR, Perez M, Kung AL,et al; p300 / MDM2 complexesparticipate in MDM2-mediated p53degradation [M];Mol Cell; 1998年 | | 6 | Shvarts A, Steegenga WT, Riteco N,et al; MDMX: a novel p53-bindingprotein with some functional propertiesof MDM2 [M];EMBO J; 1996年 | | 7 | Lin J, Chen J, Elenbas B, et al; Several hydrophobic amino acids in thep53 amino-terminal domain are requiredfor transcriptional activation, binding toMDM2 and the adenovirus 5 EIB 55 kDprotein [M];Genes Dev; 1994年 | | 8 | Watanabe T, Ichikawa A, Saito H,et al; Overexpression of the MDM2oncogene in leukemia and lymphoma [M];Leuk Lymphoma; 1996年 | | 9 | Momand J, Zambetti GP; MDM2: "bigbrother" of p53 [M];J Cell Biochem; 1997年 | | 10 | Jones SN, Roe AE, Donehower LA,et al; Rescue of embryonic lethality inMDM2-deficient mice by absence ofP53 [M];Nature; 1995年 |
|
|
|